行情

OCUL

OCUL

Ocular
NASDAQ

实时行情|Nasdaq Last Sale

4.760
+0.090
+1.93%
盘后: 4.760 0 0.00% 16:00 04/02 EDT
开盘
4.600
昨收
4.670
最高
4.840
最低
4.310
成交量
67.82万
成交额
--
52周最高
8.12
52周最低
2.350
市值
2.50亿
市盈率(TTM)
-2.4963
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测OCUL价格均价为9.00,最高价位15.00,最低价为3.000。

EPS

OCUL 新闻

更多
  • 高盛警告最糟糕情况下 标普500指数成份股盈利或锐减57%
  • 新浪美股 · 18分钟前
  • 俄罗斯据称为今年20美元的油价做准备 将发行更多债券
  • 新浪美股 · 21分钟前
  • 黄金期货周四收高2.9% 5日来首次收高
  • 新浪美股 · 24分钟前
  • 60%的美国人认为经济"糟糕" 而1月份时67%认为经济"良好"
  • 新浪美股 · 35分钟前

所属板块

医疗设备、用品及经销
+2.96%
医疗设备和用品
+3.41%

热门股票

代码
价格
涨跌幅

OCUL 简况

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
展开

微牛提供Ocular Therapeutix Inc(NASDAQ-OCUL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的OCUL股票新闻,以帮助您做出投资决策。